Femtech firms are at last enjoying an investment boom

NS Hormones are called Relaxin helps to relax the lower back of pregnant women. Without it, the pain of childbirth would be intolerable. However, after giving birth in 2014, relaxin is a woman for up to a year, as new mothers are more likely to get injured when ligaments soften, like Jessica Ennishill, an Olympic champion heptathlete discovered in training. Remains in the body of. Five years later, Dame Jessica launched Jennis, a fitness app that allows other women to perform safe postnatal training. This allowed users to optimize their training for different stages of the menstrual cycle, resulting in a successful funding round.

Listen to this story

Enjoy more audio and podcasts with iOS Also Android..

Dame Jessica startups are part of a wave of “femtech” companies that come up with ways for women to overcome gender-specific health problems. According to research firm Global Market Insights, the market could double from $ 22.5 billion last year to more than $ 65 billion by 2027. I’ve been ignoring it for years — in 2020 Femtech received just 3% of all health tech funding and to date only $ 14 billion has been invested in it — venture capitalists finally have the opportunity I’m awake. So far this year, they have invested about $ 1.2 billion in the industry, which is almost half of the 2019 annual record (see Figure 1).

Last year, Bayer, a leading German pharmaceutical company, paid $ 425 million to buy KaNDy, the UK developer of non-hormonal therapy for menopausal symptoms, and is co-founder of Microsoft’s billionaire. Bill Gates helped BIOMILQ, A startup aimed at producing cell-cultured human breast milk and bringing parents closer to newborn babies. Maven Clinic, an American startup that started as Femtech but has expanded into other health areas in August, has raised $ 110 million and achieved “Unicorn” status with a valuation of over $ 1 billion. In September, another UK company, Elvie, raised $ 97 million from a venture capital firm.

Unlike Heathtech, which targets men, it focuses on erectile dysfunction, a condition that afflicts perhaps one in ten potential users, but Femtech offers products like the Period Tracker. .. It is alive. In addition, women are 75% more likely to adopt digital tools in their health care than men. It will be a huge potential market.

A major reason for Femtech’s slow growth is related to the underlying medicine. For conditions that affect all humans, men are more commonly studied (for the same reason, mainly because of misguided concerns that hormonal fluctuations in women can confuse results. Male mice are preferred). Some more comprehensive studies rarely break down results by gender, obscuring how the disease and the drugs used to treat it affect women differently. “We’ve been acting as if women were just a small version of men,” he said, affecting everything from metabolism to pain susceptibility, a unique woman’s 29-day “circadian rhythm.” Alisa Vitti, a hormonal expert working on the “day” body clock, observes. The phenomenon has supported the tracker for many years.

As a result, many of the women’s specific health problems have been routinely ignored, despite their ubiquity. Femtechs can help fill the gap in this study. Noting that eight in ten women suffer from pre-menstrual pain, but there is no cure specifically designed to relieve it, the founder of British startup Daye said the vagina. After observing that the cannabinoids have more cannabinoid receptors than any other part of the female body, we designed a cannabidiol-contaminated tampon.

Hertility Health, also in the United Kingdom, offers non-invasive tests to help diagnose nine common gynecological disorders. Elvie’s silent wearable breast pumps are bestsellers in the United States and the United Kingdom. The app-controlled pelvic floor trainer reduces the chances of regular intervention. This allows the surgeon to “insert a fishing net and lift the pelvic organs because they have fallen from the vagina,” said Tania Borer, the company’s founder.

Labor pain

It’s a welcome progress. But too many femtechs are facing a difficult struggle. Helen O’Neill, who runs Hertility Health, calls the $ 5.7 million funding around her company, which closed in June, a “soul-destroying” process. “It was mostly white-haired men who said they didn’t know if there was a market for this,” she says. Don’t worry that every woman with a reproductive system needs gynecological help at some point. ■■

This article was published in the printed Business section under the heading “Girls uninterrupted”.

Femtech firms are at last enjoying an investment boom Source link Femtech firms are at last enjoying an investment boom

Related Articles

Back to top button